Transplantation-related mortality, treatment failures, and survival: multivariate analyses
| Covariates . | Relative risk . | 95% CI . | P . |
|---|---|---|---|
| Cox models fitted without posttransplantation covariates | |||
| Early TRM | |||
| PBPC | 1.63 | 0.87 -3.08 | .13 |
| Recipient age 35 or younger | 0.33 | 0.11 -0.93 | .036 |
| T-cell depletion | 0.34 | 0.12 -0.95 | .039 |
| Late TRM | |||
| PBPC | 0.48 | 0.23 -1.00 | .05 |
| Recipient age 35 or younger | 0.23 | 0.09 -0.60 | .002 |
| RA at last disease evaluation | 0.47 | 0.19 -1.13 | .092 |
| High-risk cytogenetics | 1.91 | 1.02 -3.58 | .044 |
| Interaction PBPC × RA at last evaluation | 6.66 | 1.78 -24.83 | .002 |
| Treatment failure | |||
| PBPC | 0.22 | 0.10 -0.48 | < .001 |
| RA at last disease evaluation | 0.19 | 0.07 -0.55 | .002 |
| Treated, not in CR MDS | 2.12 | 1.15 -3.91 | .016 |
| Event-free survival | |||
| PBPC | 0.27 | 0.13 -0.52 | < .001 |
| Recipient age 35 or younger | 0.42 | 0.24 -0.76 | .004 |
| RA at last disease evaluation | 0.41 | 0.21 -0.78 | < .007 |
| Treated, not in CR MDS | 1.86 | 1.13 -3.06 | .016 |
| High-risk cytogenetics | 1.17 | 0.62 -2.19 | .63 |
| Interaction PBPC × RA at last evaluation | 5.47 | 1.84 -16.22 | .002 |
| Interaction PBPC × high-risk cytogenetics | 3.07 | 1.10 -8.63 | .033 |
| Cox models fitted with posttransplantation covariates | |||
| Early TRM | |||
| PBPC | 1.59 | 0.69 -3.62 | .27 |
| ANC ≥ 0.5 × 109/L before day 15 | 2.62 | 1.14 -6.03 | .024 |
| Grade II-IV acute GVHD | 4.63 | 1.93 -11.12 | < .001 |
| Late TRM | |||
| PBPC | 0.33 | 0.15 -0.73 | < .007 |
| Recipient age 35 or younger | 0.26 | 0.11 -0.63 | < .003 |
| RA at last disease evaluation | 0.47 | 0.20 -1.11 | .084 |
| High-risk cytogenetics | 0.93 | 0.37 -2.31 | .87 |
| Acute GVHD | 2.69 | 1.44 -5.00 | < .002 |
| Interaction PBPC × RA at last evaluation | 6.66 | 1.78 -24.83 | < .005 |
| Interaction PBPC × high-risk cytogenetics | 4.35 | 1.20 -15.71 | .025 |
| Event-free survival | |||
| PBPC | 0.17 | 0.08 -0.37 | < .001 |
| Recipient age 35 or younger | 0.49 | 0.28 -0.85 | .011 |
| RA at last disease evaluation | 0.42 | 0.24 -0.76 | < .004 |
| High-risk cytogenetics | 0.96 | 0.54 -1.70 | .88 |
| Treated, not in CR MDS | 2.15 | 1.37 -3.40 | < .001 |
| Grade II-IV acute GVHD | 0.82 | 0.44 -1.55 | .55 |
| Interaction PBPC × RA at last evaluation | 5.20 | 1.68 -16.05 | .004 |
| Interaction PBPC × high-risk cytogenetics | 4.24 | 1.57 -11.47 | .004 |
| Interaction PBPC × acute GVHD | 3.29 | 1.21 -8.93 | .019 |
| Covariates . | Relative risk . | 95% CI . | P . |
|---|---|---|---|
| Cox models fitted without posttransplantation covariates | |||
| Early TRM | |||
| PBPC | 1.63 | 0.87 -3.08 | .13 |
| Recipient age 35 or younger | 0.33 | 0.11 -0.93 | .036 |
| T-cell depletion | 0.34 | 0.12 -0.95 | .039 |
| Late TRM | |||
| PBPC | 0.48 | 0.23 -1.00 | .05 |
| Recipient age 35 or younger | 0.23 | 0.09 -0.60 | .002 |
| RA at last disease evaluation | 0.47 | 0.19 -1.13 | .092 |
| High-risk cytogenetics | 1.91 | 1.02 -3.58 | .044 |
| Interaction PBPC × RA at last evaluation | 6.66 | 1.78 -24.83 | .002 |
| Treatment failure | |||
| PBPC | 0.22 | 0.10 -0.48 | < .001 |
| RA at last disease evaluation | 0.19 | 0.07 -0.55 | .002 |
| Treated, not in CR MDS | 2.12 | 1.15 -3.91 | .016 |
| Event-free survival | |||
| PBPC | 0.27 | 0.13 -0.52 | < .001 |
| Recipient age 35 or younger | 0.42 | 0.24 -0.76 | .004 |
| RA at last disease evaluation | 0.41 | 0.21 -0.78 | < .007 |
| Treated, not in CR MDS | 1.86 | 1.13 -3.06 | .016 |
| High-risk cytogenetics | 1.17 | 0.62 -2.19 | .63 |
| Interaction PBPC × RA at last evaluation | 5.47 | 1.84 -16.22 | .002 |
| Interaction PBPC × high-risk cytogenetics | 3.07 | 1.10 -8.63 | .033 |
| Cox models fitted with posttransplantation covariates | |||
| Early TRM | |||
| PBPC | 1.59 | 0.69 -3.62 | .27 |
| ANC ≥ 0.5 × 109/L before day 15 | 2.62 | 1.14 -6.03 | .024 |
| Grade II-IV acute GVHD | 4.63 | 1.93 -11.12 | < .001 |
| Late TRM | |||
| PBPC | 0.33 | 0.15 -0.73 | < .007 |
| Recipient age 35 or younger | 0.26 | 0.11 -0.63 | < .003 |
| RA at last disease evaluation | 0.47 | 0.20 -1.11 | .084 |
| High-risk cytogenetics | 0.93 | 0.37 -2.31 | .87 |
| Acute GVHD | 2.69 | 1.44 -5.00 | < .002 |
| Interaction PBPC × RA at last evaluation | 6.66 | 1.78 -24.83 | < .005 |
| Interaction PBPC × high-risk cytogenetics | 4.35 | 1.20 -15.71 | .025 |
| Event-free survival | |||
| PBPC | 0.17 | 0.08 -0.37 | < .001 |
| Recipient age 35 or younger | 0.49 | 0.28 -0.85 | .011 |
| RA at last disease evaluation | 0.42 | 0.24 -0.76 | < .004 |
| High-risk cytogenetics | 0.96 | 0.54 -1.70 | .88 |
| Treated, not in CR MDS | 2.15 | 1.37 -3.40 | < .001 |
| Grade II-IV acute GVHD | 0.82 | 0.44 -1.55 | .55 |
| Interaction PBPC × RA at last evaluation | 5.20 | 1.68 -16.05 | .004 |
| Interaction PBPC × high-risk cytogenetics | 4.24 | 1.57 -11.47 | .004 |
| Interaction PBPC × acute GVHD | 3.29 | 1.21 -8.93 | .019 |
ANC indicates absolute neutrophil count.